Vitrectomy With Subretinal Tissue Plasminogen Activator and Gas Tamponade for Subfoveal Hemorrhage

Abstract

An etiology other than age-related macular degeneration with less hemorrhage superior to the fovea predicts a better outcome in patients with SFH treated with pars plana vitrectomy, subretinal tissue plasminogen activator, and gas tamponade.

Macular Hemorrhage Due to Age-Related Macular Degeneration or Retinal Arterial Macroaneurysm: Predictive Factors of Surgical Outcome

“…The demographic characteristics of our patients were similar to those reported in other publications using the same surgical techniques [4,8,9]. Our patients had a mean age of 78 years, and we had a slightly higher proportion of females.…”

“…Our patients had a mean age of 78 years, and we had a slightly higher proportion of females. The majority of MaH eyes were secondary to AMD (in Plemel et al, 84.6% of included eyes were due to AMD, and 5.1% were due to RAM) [9]. Patients were managed surgically after a mean period of 7.1 days, which was in the same range as other similar publications (mean of 6.4 days in Plemel et al [9] and 4.9 days in Treumer et al [4,16]).…”

“…The majority of MaH eyes were secondary to AMD (in Plemel et al, 84.6% of included eyes were due to AMD, and 5.1% were due to RAM) [9]. Patients were managed surgically after a mean period of 7.1 days, which was in the same range as other similar publications (mean of 6.4 days in Plemel et al [9] and 4.9 days in Treumer et al [4,16]). The percentage of patients on anticoagulants or antiplatelet therapy was also comparable with other studies [4,8].…”

“…While the risk factors of macular hemorrhage have been repeatedly suggested to include (at least in AMD) systemic hypertension, antiplatelet and anticoagulant intake and possibly the anti-VEGF therapy itself [3], the prognostic factors of visual improvement after surgical therapy have been described only in a few publications [4,8,9]. The role of pro-active regimes in AMD has not been scrutinized in this context.…”

Long-Term Outcome of Anti-Vascular Endothelial Growth Factor Therapy Following Vitrectomy for Submacular and/or Vitreous Hemorrhage in Neovascular Age-Related Macular Degeneration

“…We evaluated the rate of initiation of anti-VEGF therapy after PPV for SMH and/or VH associated with nAMD. In the case of SMH caused by AMD, the rate of anti-VEGF therapy started after PPV was reported to be 38.6% for a mean follow-up period of 15.3 (range 3-70) months by Chang et al [15] and 80.8% for a mean follow-up period of 6.3 (range 2-13 months) by Plemel et al [16]. The rate of initiation of anti-VEGF therapy varies among studies because the follow-up period and the conditions for starting anti-VEGF therapy are different.…”